TriSalus Life Sciences (TLSI) - חוב לטווח ארוך להון

This Separate Debt Long Eq chart for TriSalus Life Sciences (TLSI) shows a value of 5.58. The business relies on the sustainable production of gastrointestinal therapy equipment to reduce waste. TriSalus Life Sciences (TLSI) management is implementing advanced methods for transporting drugs into liver and pancreatic neoplasms. Stable management is successfully developing pressure-driven drug delivery platforms, ensuring a rapid increase in total sales.

To minimize risks during long-term investing, it is critical to monitor the ratio of debt with a maturity of over one year to the market value of net assets. By analyzing the share of long-term loans relative to equity, an investor assesses the financial stability of TriSalus Life Sciences (TLSI) during the development of PERIO technology, where low leverage confirms the company's ability to fund clinical trials without an excessive debt burden.